Bioanalytical Strategies for CMC Characterization of Antibody-Drug Conjugates

The complex structure of antibody-drug conjugates (ADCs), a sophisticated class of targeted therapeutics that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, poses unique challenges in manufacturing pure, stable, and potent drugs to ensure proper safety and efficacy. This video and blog explores the critical bioanalytical strategies used in chemistry, manufacturing, and controls (CMC) characterization to address these challenges, highlighting the nuance of the robust CMC analytical testing that is essential for regulatory approval and patient safety, and how advanced techniques help drug developers overcome ADC complexity. 

ADC Complexity 

The starting material for an ADC is a monoclonal antibody (mAb), which possesses inherent complexity and heterogeneity due to multiple protein chains and post-translational modifications. The chemical conjugation process introduces additional layers of complexity by attaching linker molecules and cytotoxic drugs to the antibody backbone. While these chemical modification processes are well-controlled and the underlying technology is continuously improving, the chemistry itself generates substantial heterogeneity that must be carefully monitored and accounted for in any control strategy. 

This structural complexity manifests in several unique critical quality attributes (CQAs) that distinguish ADCs from conventional monoclonal antibodies, including: 

1. Drug-antibody ratio (DAR) 
2. Conjugation position of drug molecules 
3. Presence of unconjugated antibody 
4. Specific glycosylation patterns 
5. Cytotoxic bioactivity 

These attributes directly impact the therapeutic efficacy and safety profile of the final product. Therefore, effective CMC characterization requires a multi-faceted bioanalytical approach.  

Structural Analysis of ADCs 

The multi-component nature of ADCs demands advanced analytical technologies and characterization techniques capable of capturing structural variance and heterogeneity. Liquid chromatography-high resolution mass spectrometry (LC-HRMS) has emerged as a powerful tool for analyzing both intact molecules and their subunits.  

Liquid chromatography (LC) systems such as the Thermo Fisher Vanquish™ Flex employ reverse-phase columns optimized for large molecules to provide essential separation capabilities, with carefully controlled sample preparation protocols that ensure accurate characterization without artifactual changes. High resolution mass spectrometry (HRMS) systems such as the Thermo Fisher Orbitrap Exploris 240, combined with a specialized software package like BioPharma Finder, enable deconvolution of complex mass spectra and annotation and relative quantitation of detected masses against expected sequences and modifications.

Intact and Subunit Analysis 

Intact mass analysis can be used to obtain information about DAR and different ADC glycoforms; however, the inherent complexity of ADCs can make the data difficult to interpret. Consequently, enzymatic and chemical digestion strategies are used to break ADCs into subunits for more detailed assessment of specific structural features that might be obscured in intact mass analysis.

• IdeS enzyme digestion cleaves specifically at the hinge region of the ADC, separating the F(ab’)2 portion from the Fc domains. This approach reduces analytical complexity while enabling detection of process impurities, such as linkers attached without payloads, which represent CQAs that need to be monitored throughout development and manufacturing for stability and lot release.
• DTT reduction eliminates the disulfide bonds within the ADC and separates antibody chains, allowing precise determination of drug conjugation among light chain and heavy chain fragments.   

This level of detail provides essential information for understanding conjugation site specificity and batch-to-batch consistency. 

Peptide Mapping for Site-Specific Analysis 

In peptide mapping, exhaustive trypsin digestion of an intact ADC is performed to release its component peptides, enabling amino acid-level characterization of drug conjugation sites. This approach generally maintains drug attachment during digestion, allowing identification of the specific amino acids that are carrying the conjugated drug. BioPharma Finder can be used to predict the trypsinization products via in silico digest to determine the anticipated mass spectra of the resulting products. This data can be compared against the mass spectra generated by the HRMS as it fragments the peptide, monitors the masses detected, and maps them to the expected amino acid sequence of the protein to determine sequence coverage. Complete sequence coverage ensures comprehensive characterization of all potential conjugation sites. 

Bioactivity Assessment of ADCs 

Evaluating the bioactivity of ADCs involves assessment of both its cytotoxicity and its ability to bind to its target antigen to induce immune cell activation. 

Cytotoxicity bioassays 

Cytotoxicity bioassays mimic targeted drug delivery to provide a functional assessment of ADC mechanism of action. These cell-based assays typically measure dose-dependent cytotoxicity against target-expressing cells by testing serial dilutions of ADCs against reference standards to determine relative biological activity, with qualified assays typically covering 50-150% of nominal drug concentration (NDC) ranges. 

Successful assay qualification demonstrates linearity and accuracy, repeatability, and potency of a force degraded sample activity. 

Antibody-dependent cell-mediated cytotoxicity/effector function analysis 

ADCC assays evaluate the ability of the antibody portion of the ADC to engage immune effector cells. One type of such assay utilizes a nuclear factor of activated T-cells (NFAT)-responsive reporter system, such as luciferase, to generate a readout indicating that the NFAT pathway has been triggered. Validated assays typically span 50-200% NDC with similar performance criteria to cytotoxicity assays.

Impurity Characterization of ADCs 

Various impurities may arise from the ADC manufacturing process or due to degradation during storage, with direct impacts on the safety, efficacy, or stability of the therapeutic.

Host cell protein analysis 

Host cell proteins (HCPs), even at trace levels, can pose risks to patient safety by causing toxicity or immunogenicity. Standard enzyme-linked immunosorbent assays (ELISAs) use electrochemiluminescence detection to provide quantitative measurements of HCPs. However, this approach has limitations related to identification of individual HCPs, gaps in detection, and cost of reagents. 

Emerging orthogonal methods such as liquid chromatography-tandem mass spectrometry (LC-MS/MS) address these limitations by enabling identification and relative quantitation of individual HCPs without antibody dependence. While targeted approaches require stable isotope-labeled peptides, general peptide mapping provides valuable HCP monitoring throughout manufacturing and final product testing. 

Key takeaways 

CMC characterization of ADCs represents one of the most analytically challenging areas in biopharmaceutical development, requiring sophisticated analytical strategies that address the inherent complexity and heterogeneity of these multi-component therapeutics. Successful CMC characterization requires early planning and method development, and a robust control strategy demands coordination across multiple bioanalytical platforms and techniques.  

Given the technical complexity and specialized expertise required with CMC characterization, partnering with an experienced bioanalytical contract research organization (CRO), that possesses comprehensive ADC analytical capabilities across all required testing modalities, can provide critical support for successful product development and regulatory approval. 

To learn more about CMC characterization of ADCs or to discuss your project needs, contact us.